Startseite>>Peptides>> Amyloid β protein>>(Des-Glu²²)-Amyloid β-Protein (1-40)

(Des-Glu²²)-Amyloid β-Protein (1-40)

Katalog-Nr.GA20095

The Osaka mutation was the first deletion-type mutation to be identified in APP and Aβ. The Aβ E22delta mutant is more resistant to degradation by two major Aβ-degrading enzymes, neprilysin and insulin-degrading enzyme. Synthetic mutant Aβ showed unusual aggregation properties with enhanced oligomerization but no fibrillization. It also inhibited hippocampal long-term potentiation more efficiently than wild-type Aβ. A transgenic mouse model containing APP with the E693delta mutation has been developed. APP(OSK)-Tg mice exhibit intraneuronal Aβ E22delta oligomers and memory impairment as early as eight months of age.

Products are for research use only. Not for human use. We do not sell to patients.

(Des-Glu²²)-Amyloid β-Protein (1-40) Chemische Struktur

Cas No.: 1678416-36-8

Größe Preis Lagerbestand Menge
0.5mg
285,00 $
Auf Lager
1mg
486,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

The Osaka mutation was the first deletion-type mutation to be identified in APP and Aβ.The Aβ E22delta mutant is more resistant to degradation by two major Aβ-degrading enzymes, neprilysin and insulin-degrading enzyme. Synthetic mutant A

Bewertungen

Review for (Des-Glu²²)-Amyloid β-Protein (1-40)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (Des-Glu²²)-Amyloid β-Protein (1-40)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.